Progenics Pharmaceuticals Inc (PGNX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
53
About the Report
About the Report
Summary
Progenics Pharmaceuticals Inc (Progenics) is a late-stage biopharmaceutical company that focuses on developing medicines and products for the treatment of cancer and related conditions. Its only commercial product, Relistor, is used for the treatment of opioid-induced constipation. The company's pipeline comprises therapeutic agents that are designed to target cancer; PSMA-targeted imaging agents for prostate cancer that enable clinicians and patients to visualize and manage their disease; and a phase III candidate for the treatment of HIV. Progenics also offers bone scan index product EXINI Bone BSI tool and is approved for use in Europe, Japan and the US. The company markets Relistor, through a licensing agreement with Salix Pharmaceuticals outside the US except Japan. Progenics is headquartered in New York, the US.
Progenics Pharmaceuticals Inc (PGNX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Progenics Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Progenics Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
MedImmune Enters Into Licensing Agreement With Progenics Pharma For Clostridium Difficile Preclinical Program 12
Exini Diagnostics Enters into Agreement with DexTech Medical for OsteoDex 13
Licensing Agreements 14
Progenics Pharma Enters into Licensing Agreement with Selexis 14
Bayer Enters into Licensing Agreement with Progenics Pharma 15
Progenics Pharmaceuticals Enters into Licensing Agreement with Johns Hopkins University 16
Molecular Insight Pharma Enters into Licensing Agreement with University of Zurich and Paul Scherrer Institute 17
ITM Isotopen Enters Into Licensing Agreement With Progenics Pharma For Dotatoc 18
Equity Offering 19
Progenics Pharma Plans to Raise up to USD75 Million in Public Offering of Shares 19
Progenics Pharma Prices Public Offering of Shares for USD75 Million 20
Progenics Pharma Completes Public Offering Of Shares For USD 35 Million 22
Progenics Pharma Completes Public Offering Of Shares For USD 37 Million 23
Progenics Pharma Completes Public Offering Of Common Stock For USD 25 Million 24
Asset Transactions 26
CytoDyn Completes Acquisition Of PRO 140 From Progenics Pharma 26
Acquisition 28
Progenics Pharma Acquires Molecular Insight Pharma for up to USD106 Million 28
Progenics Pharmaceuticals Inc-Key Competitors 30
Progenics Pharmaceuticals Inc-Key Employees 31
Progenics Pharmaceuticals Inc-Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Recent Developments 33
Financial Announcements 33
Jul 31, 2018: Azedra's approval, progenics pharmaceuticals announces second quarter 2018 financial results and business update 33
May 09, 2018: Progenics Pharmaceuticals Announces First Quarter 2018 Financial Results and Business Update 36
Mar 08, 2018: Progenics Pharmaceuticals Announces Fourth Quarter and Full-Year 2017 Financial Results and Business Update 38
Nov 02, 2017: Progenics Pharmaceuticals Announces Third Quarter 2017 Financial Results and Business Update 40
Aug 09, 2017: Progenics Pharmaceuticals Announces Second Quarter 2017 Financial Results and Business Update 42
May 04, 2017: Progenics Pharmaceuticals Announces First Quarter 2017 Financial Results and Business Update 44
Mar 09, 2017: Progenics Pharmaceuticals Announces Fourth Quarter and Full-Year 2016 Financial Results and Business Update 46
Clinical Trials 48
Dec 06, 2017: First gastroenteropancreatic-neuroendocrine tumor (GEP-NET) patient in Europe for the COMPETE phase III clinical trial with n.c.a. 177Lu-Edotreotide (Solucin) 48
Nov 14, 2017: Successful Hosting of the Investigator Meeting for Phase III Clinical Trial COMPETE with n.c.a. 177Lu-Edotreotide (Solucin) in Cancer Patients with GEP-NET 50
Feb 14, 2017: Progenics Pharmaceuticals Announces Initiation of a Phase 1 Clinical Trial of its PSMA-Targeted Therapeutic Candidate 1095 For the Treatment of Metastatic Prostate Cancer 52
Appendix 53
Methodology 53
About GlobalData 53
Contact Us 53
Disclaimer 53
List of Figure
List of Figures
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Progenics Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
List of Table
List of Tables
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Progenics Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Progenics Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
MedImmune Enters Into Licensing Agreement With Progenics Pharma For Clostridium Difficile Preclinical Program 12
Exini Diagnostics Enters into Agreement with DexTech Medical for OsteoDex 13
Progenics Pharma Enters into Licensing Agreement with Selexis 14
Bayer Enters into Licensing Agreement with Progenics Pharma 15
Progenics Pharmaceuticals Enters into Licensing Agreement with Johns Hopkins University 16
Molecular Insight Pharma Enters into Licensing Agreement with University of Zurich and Paul Scherrer Institute 17
ITM Isotopen Enters Into Licensing Agreement With Progenics Pharma For Dotatoc 18
Progenics Pharma Plans to Raise up to USD75 Million in Public Offering of Shares 19
Progenics Pharma Prices Public Offering of Shares for USD75 Million 20
Progenics Pharma Completes Public Offering Of Shares For USD 35 Million 22
Progenics Pharma Completes Public Offering Of Shares For USD 37 Million 23
Progenics Pharma Completes Public Offering Of Common Stock For USD 25 Million 24
CytoDyn Completes Acquisition Of PRO 140 From Progenics Pharma 26
Progenics Pharma Acquires Molecular Insight Pharma for up to USD106 Million 28
Progenics Pharmaceuticals Inc, Key Competitors 30
Progenics Pharmaceuticals Inc, Key Employees 31
Progenics Pharmaceuticals Inc, Subsidiaries 32
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.